Resources Blog The Power of Computational Predictors: Antibody Developability

The Power of Computational Predictors: Antibody Developability

Biointron 2024-01-25 Read time: 4 mins
SCM.jpg
Projection of Spatial-Charge-Map (SCM) values on the Fv domain, representing viscosities. DOI: 10.1080/19420862.2015.1099773

Before the road towards clinical trials, the developability properties of therapeutic antibodies need to be evaluated. Antibody molecules are assessed for developability characteristics including aggregation, immunogenicity, pharmacokinetic clearance, viscosity, and half-life span.1 This is important to ensure a stable and efficacious drug before clinical trials.

These properties can be understood through in silico methods, such as homology modelling, docking or interface prediction. During the Lead Identification and Optimization phases these tools can help to researchers to generate three-dimensional models of the antibodies and predict or identify the key residues involved in antigen binding. Machine learning tools can also predict these properties by assessing hydrophobicity, electrostatic charge, and topology pattern interaction of the amino acid sequence.2,3 


Computational Tools

Spatial-Charge-Map (SCM) is a tool developed by Agrawal et al. (2016) that can screen monoclonal antibodies for their viscosities. SCM works by quantifying the electronegative potential patch on the Fv domain of antibodies. High viscosities, commonly found with highly concentrated antibody solutions, poses several problems to develop, manufacture, and administer the potential drug. Since the antibody sequence is a component for viscosity, this SCM tool is extremely helpful for the selection of low-viscosity antibodies.4

The therapeutic antibody profiler (TAP) is an application which compares your antibody variable domain sequence against five factors: total complementarity-determining region (CDR) length, surface hydrophobicity, asymmetry in net heavy- and light-chain surface charges, and positive charge and negative charge in the CDRs. Raybould et al. (2019) published this tool to reveal antibodies that have rare characteristics in clinical-stage mAb therapeutics.5,6 


Machine Learning Tools

Jain et al. (2017) used a random forest machine learning approach to estimate the hydrophobic chromatography (HIC) retention time directly from an antibody sequence. Quantifying hydrophobicity of a monoclonal antibody is important to assess downstream risks. The researchers successfully developed predictive models to predict the surface exposure of amino-acid side-chains in the antibody’s variable region.7

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References:

  1. Raybould, M.I.J., Deane, C.M. (2022). The Therapeutic Antibody Profiler for Computational Developability Assessment. In: Houen, G. (eds) Therapeutic Antibodies. Methods in Molecular Biology, vol 2313. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1450-1_5

  2. Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023). Computational and artificial intelligence-based methods for antibody development. Trends in Pharmacological Sciences, 44(3), 175–189. https://doi.org/10.1016/J.TIPS.2022.12.005

  3. Mieczkowski, C., Zhang, X., Lee, D., Nguyen, K., Lv, W., Wang, Y., Zhang, Y., Way, J., & Gries, M. (2023). Blueprint for antibody biologics developability. MAbs, 15(1). https://doi.org/10.1080/19420862.2023.2185924

  4. Agrawal, N. J., Helk, B., Kumar, S., Mody, N., Sathish, H. A., Samra, H. S., Buck, P. M., Li, L., & Trout, B. L. (2016). Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs, 8(1), 43-48. https://doi.org/10.1080/19420862.2015.1099773

  5. J. Raybould, M. I., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019). Five computational developability guidelines for therapeutic antibody profiling. Proceedings of the National Academy of Sciences of the United States of America, 116(10), 4025-4030. https://doi.org/10.1073/pnas.1810576116

  6. James Dunbar and others, SAbPred: a structure-based antibody prediction server, Nucleic Acids Research, Volume 44, Issue W1, 8 July 2016, Pages W474–W478, https://doi.org/10.1093/nar/gkw361

  7. Jain, T., Boland, T., Lilov, A., Burnina, I., Brown, M., Xu, Y., & Vásquez, M. (2017). Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning. Bioinformatics, 33(23), 3758-3766. https://doi.org/10.1093/bioinformatics/btx519

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024
Blog

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024
Blog

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024
Blog

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024
Blog

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.